UB-312 is under clinical development by Vaxxinity and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect UB-312’s likelihood of approval (LoA) and phase transition for Lewy Body Dementia took place on 25 Aug 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their UB-312 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

UB-312 overview

UB-312 is under development for the treatment of Parkinson's disease and multiple system atrophy (MSA) and for dementia with lewy bodies. The vaccine candidate is an endobody, it acts by targeting alpha-synuclein protein. It is developed based on synthetic peptide vaccine technology.

Vaxxinity overview

Vaxxinity is a biotechnology company that enables the innovation of synthetic peptide vaccines to prevent or treat infectious diseases. It offers an innovative platform that has the power to activate different arms of the immune system selectively and to neutralize targets with high specificity. The company is headquartered in Dallas, Texas, the US.

Quick View UB-312 LOA Data

Report Segments
  • Innovator
Drug Name
  • UB-312
Administration Pathway
Therapeutic Areas
  • Central Nervous System
Key Developers
  • Sponsor Company: Vaxxinity
  • Originator: United Neuroscience
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.